A New Index-Based Investing Alternative to ETFs is Coming Soon Print E-mail
Wednesday, 24 February 2010 08:44

Coming soon is a premium service offered in collaboration with Investars YOU for full access to a global database that includes over 900 stocks which are organized and managed within my 18 HavRx Stock Indexes.

 

My actively managed indexes include Regulatory Catalyst and Emerging Cancer Dx / Tx while the remaining 15 indexes are passively managed.

This co-branded subscription service will provide investors with the flexibility to create their own customized, index-based portfolios (YOUs) at the Investars YOU website (which is being revamped to make the site more user friendly) as an alternative to the automated, auto-rebalanced investment options with online brokers / advisors such as thinkorswim, which are described below. In addition, premium subscribers to my co-branded service will have access to the following options to view both current and historical stock index components: (1) only current components, (2) all historical components, (3) only US current components, and (4) historical US components.

Investors will have the ability to create YOUs based on their personal preferences, beliefs, and investment opinions through the specialized stock indexes appearing at the site that are organized and targeted toward a wide variety of market themes and trends with initial pricing of $60 per year for a limited time and standard pricing of $99 per year for my co-branded subscriptions service.

Investars YOU is also establishing relationships with online brokers / advisors such as thinkorswim so that investors can allocate funds on an equal-weight basis across all index component stocks and the service will also include auto-rebalancing to reflect updates in the indexes.

TD Ameritrade (NASDAQ: AMTD) acquired thinkorswim in June 2009 and is currently in the process of integrating the broker / advisor operations, in addition to other pending agreements to make the personalized, stock index-based investing service of Investars YOU available to additional online trading / investing platforms.

I have opened an account with thinkorswim for both the online brokerage / advisory group and plan to make initial investments across some of my indexes within the next few weeks, including Regulatory Catalyst, Generic Drugs, and / or Emerging Cancer Dx / Tx.

My stock indexes were originally designed to be commercialized as exchange-traded funds (ETFs) through XShares / HealthShares through a partnership that I formed with the latter Company's CEO called ETF Innovators, LLP, which has since been dissolved. HealthShares has removed all of their sub-sector healthcare ETFs from the market due to lack of commercial success, but this is not necessarily reflective of the performance of the underlying indexes and future growth potential for segments within the sector such as stem cells, generic drugs, and immune therapies / vaccines.

Many of these indexes continue to exhibit strong fundamentals and have outperformed both the healthcare sector and the overall market such as generic drugs, health benefit providers, emerging cancer diagnostic / therapeutic developers, and regulatory catalyst companies (i.e. pending FDA decisions or pivotal clinical trial results).

The table above includes performance statistics and other details for my 18 HavRx Stock Indexes. Click on any of the indexes below for a link to the Investars YOU website for the most recent data and details for each index (in the same format as the performance summary snapshot for the Regulatory Catalyst Index). The Investars YOU website also includes a drop-down box with the option 'more indices by this publisher' to view the performance summaries for each of my 18 HavRx Stock Indexes.

The actively managed HavRx Regulatory Catalyst Index tracks the performance of select healthcare companies with pending new drug, biological agent, medical device, and diagnostic product applications at the FDA. The index also tracks select healthcare companies with pending pivotal clinical trial results that are designed to support a new filing or resubmission for FDA approval.

The HavRx Diabetes Care Index is passively managed and tracks the performance of companies which derive the majority of revenue from diabetes care products, have double-digit market share for any type of diabetes care market, and / or have a diabetes care product in development.

The HavRx Cosmetic / Restorative Medicine Index is passively managed and tracks the performance of companies that are actively developing and / or derive the majority of revenue from any of the following activities: (1) prescription skin care therapeutics; (2) medical devices, products, services, OR equipment for procedures which are intended to enhance appearance; (3) medical devices, products, services, OR equipment for use as joint replacements, tissue repair agents, tissue reconstruction agents, surgical adhesives, and cardiovascular procedures; and (4) regenerative medicine products, services, and/or an active clinical pipeline which seeks to restore or repair the functionality of lost or damaged organ, tissue, cellular, and genetic material.

The HavRx Life Science Leaders Index is passively managed and tracks the performance of companies with market caps of at least $20 billion at the time of index inception that derive the majority of revenue from any type of healthcare product or service, medical device / diagnostic, drug / biological agent, and agri-biotech (crop science and seeds).

The HavRx Natural Health Index is passively managed and tracks the performance of companies that manufacture, distribute, or sell any type of non-prescription, over-the-counter (OTC) vitamin / mineral product, herbal / natural remedy, nutraceutical, functional / organic food, or other type of health supplement / enhancement product.

The HavRx Immune Therapy / Vaccines Index is passively managed and tracks the performance of companies with market caps below $20 billion at the time of index inclusion which are developing or commercializing any type of cancer immunotherapy or therapeutic / preventative vaccine product that is designed to stimulate the immune system for the eradication, combination treatment, or prevention of cancer. In addition, the index will track companies which are developing or commercializing any type of vaccine product or vaccine adjuvant for all types of infectious disease such as influenza (flu) and bio-defense applications.

The actively managed HavRx Emerging Cancer Diagnostic / Therapeutic (Dx / Tx) Index constituents reflect a cross-section of emerging cancer companies with market caps below $500 million at the time of index inclusion, encompassing the following categories: (1) diagnostics (molecular diagnostics and device-based diagnostics), (2) lab services (personalized medicine applications to guide and track the effectiveness of cancer treatments), (3) drug discovery (screening and modifying compounds to achieve anti-cancer effects during the early stages of preclinical and Phase 1 clinical studies), (4) immunotherapy (a.k.a. cancer vaccines which are designed to stimulate the immune system to eradicate cancer), and (5) commercial or late-stage (Phase 2-3) clinical development therapeutics, devices, or diagnostics intended for use by cancer patients.

The HavRx Global Generic Drug Index is passively managed and tracks the performance of companies which meet any of the following three requirements: (1) Derive either $500 million (USD) OR more than 50% of trailing 12-month revenue from the manufacture and sale of any type of generic (off-patent) prescription or over-the-counter (OTC) drug product intended for use by humans, including contract manufacturing services, active pharmaceutical ingredient (API) suppliers, and intermediate product suppliers for drug products and biological agents; (2) Have one or more compound(s) in active clinical development OR have a pending ANDA with the FDA for a generic drug candidate; (3) Receive FDA approval for an ANDA within the past 12 months. The index excludes all companies that derive over 50% of trailing 12-month revenue from the sale of patent-protected or legacy brand prescription or OTC drug products.

The HavRx Global Health Information Technology (Health IT) Index is passively managed and tracks the performance of companies with market caps below $10 billion that derive over either $50 million or 50% of their trailing 12-month revenue from products and services for the following activities: (1) electronic transmission, storage, and processing of prescriptions; (2) secure e-mail transmission for healthcare facilities; (3) electronic transmission, storage, and processing of medical imaging and diagnostic information; (4) electronic storage and systems for administrative functions of healthcare facilities and medical records; (5) electronic transmission, storage, and systems for healthcare market data and clinical trial data; (6) electronic systems, devices, and services for remote, real-time monitoring of patient health parameters; (7) medical transcription services, products, and systems for conversion into electronic medical records.

The HavRx Global Hospital Index is passively managed and tracks the performance of companies which derive the majority of their revenue from the following activities: hospitals, inpatient rehabilitation facilities, dialysis facilities, blood banking services / equipment, hospice providers, inpatient behavioral healthcare facilities, ambulatory surgery centers, and hospital service / equipment providers. The revenue requirement for this index excludes the following activities: home healthcare, outpatient medical services, and senior living centers.

The HavRx Stem Cells Index is passively managed and tracks the performance of regenerative medicine companies that derive the majority of their revenue or have compound(s) in active pre-clinical or clinical development which are designed to restore, replace, repair, or enhance the functionality or appearance of tissue and organ systems, including all types of embryonic and adult stem cell therapeutics. In addition, all types of products and services for stem cell banking are included in this index.

The HavRx Health Benefit Providers Index is passively managed and tracks the performance of retail pharmacies, pharmacy benefit managers, managed care companies, health insurers, hospital pharmacy operators, workers compensation insurers, and specialty health benefit providers.

The HavRx Global Crop Science Index is passively managed and tracks the performance of companies that derive the majority of their revenue from any of the following agricultural business activities: fertilizers, potash, farming, seeds, insecticides, herbicides, and other ag-related chemicals.

The HavRx Global Clean-Tech Index is passively managed and tracks the performance of companies which either generate carbon credits through their business operations, are involved with the trading of carbon credits, or reduce carbon emissions through their business activities. In addition, the index may include companies that supply renewable energy products, services, and raw materials / resources for applications such as waste-to-energy, landfill / methane gas collection, clean energy / bio-fuels, smart electric grid / power management, energy efficiency, water supply infrastructure, and all other forms of alternative energy such as wind, solar, battery, and hydropower.

The HavRx Global Railroad Industry Index is passively managed and tracks the performance of companies that derive either more than 50% OR $100 million of trailing 12-month revenue from any of the following activities: (1) passenger or freight rail transport services; (2) railcar and locomotive leasing; (3) railcar and locomotive fleet management; (4) rail infrastructure, railcar, locomotive, and railcar/locomotive component parts manufacturing; (5) railcar, locomotive, and component parts repair or refurbishment. 

The HavRx Global Tobacco Industry Index is passively managed and tracks the performance of companies that are actively developing and / or derive the majority of revenue from the distribution / manufacturing of any type of tobacco product (e.g. cigarettes, cigars, chewing tobacco), tobacco supplies (e.g. wrapping papers, tobacco leafs, filters), modified risk tobacco products (MRTP), and electronic cigarettes (e-cigarettes).

The HavRx Global Trucking / Logistics Index is passively managed and tracks the performance of companies with market caps over $100 million at the time of inclusion that derive at least 50% of trailing 12-month revenue from any of the following activities: logistics and management support services for all types of transportation companies; all types of land-based, roadway freight forwarding freight transportation services; mail package delivery, transportation, and logistics services; and logistics management support services for roadway transportation companies.

The HavRx Global Air Transport Index is passively managed and tracks the performance of companies that derive the majority of their revenue from passenger airline services, helicopter transport services, and air freight transport activities.

Disclosure: No positions




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter